Non-Steroidal Anti-inflammatory Drugs Market Report 2026

The non-steroidal anti-inflammatory drugs market size has grown strongly in recent years. It will grow from $21.89 billion in 2025 to $23.31 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing prevalence of arthritis and musculoskeletal disorders, rising awareness of pain management therapies, growth in geriatric population, expansion of retail pharmacies, advancements in drug formulation technologies.

The non-steroidal anti-inflammatory drugs market size is expected to see strong growth in the next few years. It will grow to $29.96 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to adoption of personalized medicine, growth of e-pharmacy platforms, increasing r&d in novel nsaid formulations, rising incidence of chronic inflammatory diseases, integration of digital health solutions for pain monitoring. Major trends in the forecast period include personalized pain management solutions, rising demand for otc anti-inflammatory drugs, development of rapid-acting formulations, focus on chronic pain and arthritis management, expansion of online pharmacy channels.

The growing prevalence of musculoskeletal disorders is expected to drive the expansion of the non-steroidal anti-inflammatory drug market in the coming years. Musculoskeletal disorders (MSDs) encompass a wide range of conditions that affect the musculoskeletal system, including muscles, bones, tendons, ligaments, joints, and other connective tissues. Non-steroidal anti-inflammatory drugs (NSAIDs) play a vital role in managing pain and inflammation associated with conditions such as arthritis, osteoarthritis, and rheumatoid arthritis. Contributing factors to this growth include the aging population, greater awareness and diagnosis of musculoskeletal disorders, orthopedic procedures, sports-related injuries, and the chronic nature of these conditions. For example, in January 2024, the UK-based government department GOV.UK reported that in 2023, 18.4% of individuals aged 16 and older reported having a long-term musculoskeletal (MSK) condition, an increase from the 17.6% prevalence recorded in 2022. As a result, the rising prevalence of musculoskeletal disorders is fueling the growth of the non-steroidal anti-inflammatory drugs market.

The increasing prevalence of chronic pain is anticipated to propel the growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market and associated pain management solutions in the coming years. Chronic pain refers to persistent or recurrent pain that lasts for three months or more, often resulting from conditions such as arthritis, fibromyalgia, back pain, neuropathic pain, and other musculoskeletal disorders. These conditions have a profound impact on patients' quality of life and frequently require long-term management, which may include medication, physical therapy, and supportive care. As chronic pain becomes more prevalent, the demand for effective pain relief treatments, such as NSAIDs and other analgesic formulations, continues to rise. For example, in October 2024, the National Center for Biotechnology Information, a U.S.-based federal government research agency, reported that 24.3% of adults experienced chronic pain, with 8.5% suffering from high-impact chronic pain that limits daily activities. As a result, the growing number of individuals affected by chronic pain is expected to drive demand for pain management therapies, thereby supporting the expansion of the NSAIDs market and related products.

Leading companies in the non-steroidal anti-inflammatory drugs (NSAIDs) market are focusing on developing innovative solutions, such as combination analgesic-gastroprotective formulations, to address the growing demand for effective pain relief with reduced gastrointestinal risks typically associated with long-term NSAID use. These combination technologies pair an NSAID with a protective agent, allowing for the retention of anti-inflammatory efficacy while minimizing stomach irritation, offering a safer alternative to traditional single-agent NSAIDs. For example, in March 2024, Endo International plc, an Ireland-based pharmaceutical company, introduced ibuprofen-famotidine 800 mg/26.6 mg tablets. This advanced formulation combines the analgesic and anti-inflammatory properties of ibuprofen with the gastroprotective benefits of famotidine. The dual-action tablet is designed to relieve pain while reducing gastrointestinal side effects like ulcers or irritation, which often arise with extended NSAID use, thereby enhancing safety and promoting better patient adherence.

Major companies operating in the non-steroidal anti-inflammatory drugs market are Pfizer Inc., Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Assertio Therapeutics Inc., Iroko Pharmaceuticals Inc., Perrigo Company PLC, Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Limited, Aspen Pharmacare Holdings Limited, Sagent Pharmaceuticals Inc., Advanced Pharma Inc., Akorn Operating Company LLC, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Zydus Cadila Healthcare Limited, Aurobindo Pharma Limited, Sanofi S.A., GlaxoSmithKline PLC, Horizon Therapeutics PLC, Novartis AG, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company.

North America was the largest region in the non-steroidal anti-inflammatory drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-steroidal anti-inflammatory drugs market during the forecast period. The regions covered in the non-steroidal anti-inflammatory drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-steroidal anti-inflammatory drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created both challenges and opportunities for the non-steroidal anti-inflammatory drugs market by affecting the cost of raw materials, active pharmaceutical ingredients, and imported formulations. The resulting increase in production costs impacts oral and topical segments, particularly in regions like Asia-Pacific and Europe where imports are significant. Hospitals and retail pharmacies face higher procurement costs, while manufacturers are exploring local production and alternative sourcing strategies. Some positive effects include encouraging domestic manufacturing and boosting investment in local supply chains.

The non-steroidal anti-inflammatory drugs market research report is one of a series of new reports that provides non-steroidal anti-inflammatory drugs market statistics, including non-steroidal anti-inflammatory drugs industry global market size, regional shares, competitors with a non-steroidal anti-inflammatory drugs market share, detailed non-steroidal anti-inflammatory drugs market segments, market trends and opportunities, and any further data you may need to thrive in the non-steroidal anti-inflammatory drugs industry. This non-steroidal anti-inflammatory drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-steroidal anti-inflammatory drugs are medications that help decrease inflammation and reduce fever. They are commonly used to treat conditions such as headaches, sprains, strains, menstrual pain, colds and flu, arthritis, and various chronic pain issues. These drugs help alleviate inflammation, ease pain, and lower elevated body temperature.

The primary routes of administration include oral, topical, and other methods. Topical formulations are typically used to relieve muscle pain, sprains, and strains, as well as to alleviate the discomfort caused by arthritis. These drugs are indicated for conditions such as arthritis, migraines, ophthalmic diseases, and other medical conditions, and are available in hospital pharmacies, retail pharmacies, and online pharmacies.

The non-steroidal anti-inflammatory drugs market consists of sales of high-dose aspirin, indomethacin, mefenamic acid, celecoxib, and other types. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.